<DOC>
	<DOCNO>NCT02981472</DOCNO>
	<brief_summary>To investigate safety pharmacokinetics apixaban child congenital acquire heart disease need anticoagulation .</brief_summary>
	<brief_title>A Study Safety Pharmacokinetics Apixaban Versus Vitamin K Antagonist ( VKA ) Low Molecular Weight Heparin ( LMWH ) Pediatric Subjects With Congenital Acquired Heart Disease Requiring Anticoagulation</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>For information regard BristolMyers Squibb Clinical Trial participation , please visit www.BMSStudyConnect.com Males female , 34 week adjust gestational age &lt; 18 year age Congenital acquire heart disease require chronic anticoagulation thromboprophylaxis ( eg , single ventricle physiology include 3 stage palliation , dilate cardiomyopathy , Kawasaki disease coronary aneurysm , pulmonary hypertension ) Eligible patient include newly start anticoagulant currently VKA LMWH anticoagulant thromboprophylaxis Able tolerate enteral medication [ eg , mouth , nasogastric tube , gastric tube ] Recent thromboembolic event le 6 month prior enrollment Use aggressive lifesaving therapy ventricular assist device ( VAD ) extracorporeal membrane oxygenation ( ECMO ) time enrollment Prosthetic heart valves mechanical heart valve Known inherit bleed disorder coagulopathy ( e.g . hemophilia , von Willebrand disease , etc . ) Active bleed time enrollment Any major bleed perioperative precede 3 month Known intracranial congenital vascular malformation tumor Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>34 Weeks</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>